AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...

AstraZeneca believes the taxes are related to cancer drug Imfinzi, but Enhertu could be implicated as well, Leerink Partners analyst Andrew Berens said. Enhertu is a breast cancer treatment.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

Daiichi Sankyo and AstraZeneca’s (AZN) Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...